A researcher examining vials and a test-tube rack in a laboratory
Biologics

Biologics GMP Compliance Coaching

For biologics manufacturers: GMP gap diagnosis, sterility assurance and contamination control strategy (CCS) coaching, readiness for regulatory inspections and customer audits, and coordination of related testing plans.

  • Market route first
  • Evidence files aligned
  • Less rework before audits

Biologics Compliance Challenges

Biologics put process control at the centre: sterility assurance, process consistency and data integrity are the recurring focus of both regulatory inspections and customer audits.

Sterility Assurance & CCS

Sterile biologics cannot be proven sterile unit by unit through end-product testing; the revised EU GMP Annex 1 (in force since 25 Aug 2023) requires a contamination control strategy (CCS) spanning cleanrooms, sterilisation, environmental monitoring and personnel behaviour.

Multiple GMP Frameworks

Each destination market inspects against its own GMP text: in the U.S., 21 CFR 210/211 read together with the biologics regulations (Parts 600–680); in the EU, EudraLex Volume 4; PIC/S members inspect to the PE 009 guide — the site must align all of them at once.

Process Consistency & Change Control

Biologics quality depends heavily on the process itself; process changes, site transfers and scale-up all require complete change control, validation evidence and traceable records that auditors check item by item.

Data Integrity

FDA's data integrity guidance also covers biologics: batch records, laboratory data and audit trails must meet ALCOA+ principles, with management and operators each accountable for their part of data control.

Related Compliance Support

QTC works to biologics GMP and sterile-control requirements: first map the gaps, then build the system and evidence for regulatory inspections and customer audits.

Biologics GMP Gap Diagnosis

2-3 weeks

For: Biologics manufacturers preparing for a GMP inspection or a major customer audit who need a clause-by-clause gap review against the target-market GMP first.

Key Goal

Goal: see the gaps and priorities first, then drive targeted remediation

What you get
  • Gap list and priorities against target-market GMP (21 CFR 210/211, EU GMP, PIC/S PE 009)
  • Review of sterility assurance and CCS critical control points
  • Data integrity (ALCOA+) current-state assessment
  • Remediation roadmap and inspection-readiness document list

Sterility Assurance & System Build Coaching

Staged

For: Sites building or upgrading sterile biologics lines that need a CCS and aseptic-process system built to the revised Annex 1.

Key Goal

Goal: turn sterility assurance from paper requirements into site controls and evidence an inspector can verify

What you get
  • CCS document framework with item-by-item implementation coaching
  • Control requirements for cleanrooms, environmental monitoring and gowning behaviour
  • Readiness review for aseptic process validation (media fills and related studies)
  • Evidence-chain organisation for deviations, changes and CAPA

Inspection & Audit Readiness Coaching (Mock Audit)

Scheduled to the inspection plan

For: Sites with a regulatory inspection or customer audit scheduled that need a full rehearsal and issue closure beforehand.

Key Goal

Goal: close known issues before the real inspection and have evidence ready to retrieve on request

What you get
  • Mock audit against the target-market GMP with a findings list
  • Inspection document pack structure and evidence index
  • Coaching on site-tour and interview readiness
  • CAPA closure tracking for mock findings

Biologics Testing Plan Coordination

Project-based

For: Biologics manufacturers that need testing plans designed and qualified laboratories arranged — sterility, microbiology or manufacturing-component testing.

Key Goal

Goal: align test items, standards and timing in one pass, with evidence ready for inspections and customer audits

What you get
  • Testing needs list mapped to applicable standards (e.g. USP <665> for plastic components and single-use systems in manufacturing, official 1 May 2026)
  • Test plan design and submission scheduling
  • Qualified laboratory arrangement and report review support
  • Testing evidence filed into the inspection-readiness pack

Core Regulatory Frameworks for Biologics

The GMP and sterile-manufacturing frameworks governing biologics for the U.S., EU and PIC/S markets.

21 CFR 210/211 + Parts 600–680

The U.S. finished-drug cGMP framework, read together with the biologics licensing regulations (Parts 600–680) as complements, not substitutes.

EU GMP Annex 1

The EU sterile-manufacturing annex; the revised version applies from 25 Aug 2023 and centres on the contamination control strategy (CCS) and end-to-end sterility assurance.

PIC/S GMP (PE 009)

The GMP guide used jointly by PIC/S member inspectorates — current version PE 009-18 — a key alignment baseline for multi-market exporters.

USP <665>

Requirements chapter for plastic components and systems used in manufacturing drug and biopharmaceutical products (incl. single-use systems), official 1 May 2026.

Data Integrity (FDA Guidance)

FDA's data integrity and cGMP compliance guidance covers finished drugs and biologics, centred on ALCOA+ and audit trails.

Frequently Asked Questions

Answering common questions on GMP inspections, sterility assurance and customer audits for biologics manufacturers.

The framework is shared: GMP applies to manufacturing, processing, packing or holding drugs including biologics — 21 CFR 210/211 in the U.S. and EudraLex Volume 4 in the EU. But U.S. biologics also read together with the Parts 600–680 licensing regulations, and inspections emphasise sterility assurance and process consistency, so alignment must be done clause by clause for biologics specifics.

Sustainability & ESG

Do Your Buyers Also Request ESG Evidence?

Pharma brands and manufacturers increasingly face social audits (EcoVadis, CDP, carbon footprints, human rights) alongside standard GxP/cGMP quality requirements.

Why QTC

The value of quality coaching rests on a repeatable closed-loop method, field-based coaching capability, and a clear division of work.

Four-step closed loop
1

Diagnose

Run a gap diagnosis against the target scheme and produce a gap list with priorities.

2

Build

Build the system, documents and evidence packs per the gaps.

3

Verify

Verify the system works through a mock audit / pre-audit.

4

Close

Close CAPA evidence, then re-check before the re-audit.

Coaching capability profiles

Pharma GMP (21 CFR 210/211, ICH Q7)

Coaches gap diagnosis, PAI readiness and timed 483/Warning Letter response; delivers gap lists, CAPA plans and evidence packs.

Excipients & Packaging (EXCiPACT, ISO 15378)

Coaches certification readiness, document and system build and mock audits; delivers scheme benchmark tables and pre-audit reports.

Devices & Supplements (ISO 13485, 21 CFR 111, 455-2)

Coaches QMSR implementation, 455-2 readiness and gap diagnosis; delivers gap lists and evidence packs.

Coach backgrounds

Formerly with Intertek, BV, SGS, NSF and similar bodies

5000+ · QTC Group service cases

QTC's own audit team

Audits are carried out by QTC's own team. Our auditors are experienced, several with audit backgrounds at large certification bodies; they undertake buyer-commissioned second-party audits and pre-audits and issue assessment reports.

Anonymised case

A pharmaceutical manufacturer · GMP inspection readiness

Trigger: a customer PAI was approaching, and the client's own self-inspection had flagged data integrity and deviation handling as high-risk. Work: clause-by-clause gap diagnosis against 21 CFR 210/211 and ICH Q7, SOP and record rebuild per the gaps, a full mock inspection, and item-by-item CAPA closure. Outcome: the gap list and CAPA were fully closed on schedule, the readiness evidence pack was assembled in one pass, and the formal inspection proceeded as planned.

Boundary statement

Certificates, verification statements and test reports are issued by the accredited body or laboratory that performs the work; formal audits are performed by accredited bodies, scheme owners, or the buyer's own auditors.

Need a biologics GMP gap review or inspection readiness support?

Tell us your product type and target markets — we will map the gaps and the preparation order first.

Contact QTC